1. Introduction
Huntington’s disease (HD) is genetically inherited in an autosomal dominant fashion. It is a fatal neurodegenerative disease, caused by an abnormal triplet repeat expansion of CAG (cytosine-adenine-guanine) within the huntingtin (HTT) gene on chromosome 4p16.3, causing a mutated huntingtin protein (mHTT) [1,2,3,4,5]. HD is predominantly characterized by adult-onset, progressive motor dysfunction, cognitive impairment and psychiatric symptoms (depression, anxiety, obsessive-compulsive disorder, and psychosis). Chorea, incoordination, and rigidity are common motor symptoms due to neurotoxicity of mHTT, leading to brain atrophy of the striatum, thalamus, cerebellum, brain stem and cortex [6,7,8,9]. Clinically, HD includes juvenile HD (onset less than 21 years, and marked clinical symptoms), and late-onset HD (after the age of 60 years) [10,11,12]. Alcohol, drug, and tobacco abuse were associated with earlier onset of HD, and hasten motor onset in women. These abuses have more significant associations in females than in males [13,14]. Children with CAG repeats ≥39, had significantly lower measures of head circumference, weight, and body mass index [15,16,17]. Disrupted sleep, tics, pain, itching, and psychosis are the common symptoms of juvenile HD [18].
Presently, there is no remedy for HD, and the disease progresses manifests with a presumed continuation of 15–20 years after the appearance of the first symptom [12,19]. The identification of novel biomarkers involves the development of new treatment strategies. The current therapy is palliative and does not change the course of the disease. Tetrabenazine (TBZ; Xenazine™) was approved for the remedy of chorea in HD by the U.S. food and drug administration (FDA). Additionally, the deuterated version of TBZ, deutetrabenazine (AUSTEDO™), has an improved pharmacokinetic profile and was recently approved by the FDA for the treatment of Huntington chorea. In the last review [20], we discussed different promising agents in the treatment of HD, and their phases under clinical trial. Here we describe updates related to these promising agents which will cure HD.
2. Pathogenesis of the HD
HD is a monogenic disease with prevalence of about 1 in 7,500 individuals in the general population [21,22]. The normal allele has less than 27 CAG repeats and intermediate alleles have 27–35 repeats. CAG repeats of 36–39 will develop HD with less penetrance. Individuals who have 40 or more CAG repeats will develop HD with full penetrance. It is also reported that the higher the CAG expansion, the earlier the onset and the greater the disease severity [12,23]. Kremer et al. reported the largest expansion of 121 trinucleotides [24]. CAG codon encodes glutamine α-amino acid (symbol Gln or Q). Glutamine (C5H10N2O3) is synthesized from glutamate and ammonia by the enzyme glutamine synthetase. It is mainly produced in muscle, the lungs, and the brain and acts as a precursor to the neurotransmitter glutamate [25]. CAG has glutamine amino acids within the HTT gene and it is not toxic in itself. However, the polyglutamine expansion involves the formation of aggregate and ultimately becomes toxic. It is the principal factor for the manifestation of HD because aggregates are never a remarkable feature in the brain of normal subjects [26,27]. Aggregate formations are accountable for secondary problems, like inflammatory responses (altered cytokine and nitric oxide level), mitochondrial dysfunction (imbalanced level of free radicals and oxidative stress markers), nuclear cleavage, apoptosis, excitotoxicity, transcriptional altered regulation, and lastly, are responsible for the altered neuropathological feature (cause of cell death/damage) (Figure 1). Approximately 70% of the variation of the disease is due to expanded CAG repeats, while 13% of the variation is due to polymorphisms in the GRIK2 gene [28]. These depict the importance of secondary factors that affect disease onset, its severity, and possible output.
3. Therapeutic Update
Currently, many drugs are under clinical trial. In the following subsection, we discuss their therapeutic status and their potential role in treatment. These drugs are summarized in Table 1 and Figure 2.
3.1. Drugs against Excitotoxicity
3.1.1. Riluzole and Memantine Drug
Riluzole is a glutamate inhibitor that reduces abnormal movement in amyotrophic lateral sclerosis (ALS) patients [29,30]. In a double-blinded trial, riluzole did not decrease symptoms of HD, nor was it neuroprotective [31].
Memantine is an antagonist of extrasynaptic N-methyl-D-aspartate (NMDA) receptors and is used for the treatment of moderate-severe dementia in Alzheimer’s disease (AD). It diminishes striatal cell death, hinders disease progression and improves cognitive function related to HD [32,33]. The combination of memantine and risperidone prevented the expected progression of motor symptoms, cognitive decline, and psychosis over a 6-month study period [34]. However, memantine dosing may be critical, as rodents on low-dose memantine had decreased pathology, while a high-dose of memantine worsened rodent outcomes and possibly promoted cell death [35,36,37].
3.1.2. Tetrabenazine (TBZ) and Deutetrabenazine
TBZ inhibits the dopamine pathway by inhibiting vesicular monoamine transporter (VMAT) type 2 and consequently decreases available dopamine in the synapse and its interaction with postsynaptic dopamine receptors [38,39,40]. Deutetrabenazine contains a deuterium atom and is a novel inhibitor of VMAT2. In indirect treatment comparison studies, deutetrabenazine was found to have a favorable tolerability profile compared to tetrabenazine [41]. In mouse models, TBZ ameliorated chorea and other motor symptoms, and reduced striatal neuronal cell loss [38].
3.2. Targeting Caspase Activities and Huntingtin Proteolysis
Minocycline
Minocycline is a tetracycline analog and can cross the blood–brain barrier (BBB) and inhibits the expression of caspase-3 and caspase-1 [42,43]. Treatment with minocycline proved to be neuroprotective, and to improve the disease phenotype [30,42,44]. A human trial study observed motor (unified HD rating scale (UHDRS)), and cognitive (mini-mental state examination (MMSE)) improvement in 14 HD patients who took 100 mg of minocycline for 6 months [43]. This study was continued for another 18 months, and it was found that MMSE, TMS, total functional capacity (TFC) and independence scale were all stabilized after treatment, reducing the expected decline in these measures. There was also a decrease in psychiatric symptoms at 24 months, which was not apparent after 6 months of treatment [44]. In a pilot study, Thomas et al. found improvement in MMSE, UHDRS, and abnormal involuntary movements scale (AIMS), in 30 patients with HD who were given minocycline for 6 months [45].
3.3. Targeting HTT Aggregation and Clearance
3.3.1. Congo Red and Trehalose
Congo red dye binds preferably to β-sheets with amyloid fibrils. When injected into HD mice, it preserved normal protein synthesis and degradation, and improved motor functions. This dye promotes clearance of expanded polyQ repeats and inhibits polyglutamine oligomer formation through the disruption of preformed oligomers. Congo red dye also prevented ATP depletion and caspase activation [46,47,48].
Trehalose disaccharide inhibited the formation of nuclear inclusions, improved altered motor function and was associated with a high rate of survival in R6/2 mice without causing harmful side effects [49,50,51] (Table 1 and Figure 2).
3.3.2. Compound C2–8
Compound C2–8 inhibits polyglutamine aggregates in brain slices and cell cultures. It has improved motor function, decreased the amount of neuronal atrophy, and decreased the size of the mHTT aggregates in R6/2 mice [52,53]. There is no ongoing human trial using this compound currently listed on
3.3.3. Rapamycin
mTOR is a protein kinase that phosphorylates many proteins and plays a key role in various cellular functions (like autophagy and transcription). mTOR interacts with mHTT and localizes to these polyglutamine aggregates, and thus sequestration of mTOR reduces the activity of mTOR, resulting in a decrease in autophagy and a decrease in the clearance of mHTT. mTOR phosphorylates S6K1 (a key regulator of cell volume), therefore mHTT-related impairment of mTOR may account for the brain atrophy in HD. Rapamycin (which inhibits mTOR and consequently induces autophagy) decreased mHTT aggregates and improved neuronal survival in the drosophila HD model. Rapamycin also improved motor performance and decreased striatal neuropathology in mouse models of HD [54,55,56].
3.4. Targeting Mitochondrial Dysfunction
3.4.1. Creatine
Creatine (with antioxidant properties) reduced serum levels of 8-hydroxy-2′-deoxyguanosine (8-OH-2′-dG) in HD patients [85,86] and is safe and tolerable at a dose of 15 g twice daily [87]. In a trial study (with HD patients), receiving a dose of 8 g/day of creatine was secure and well-tolerated but produced no marked change on the UHDRS scale [86]. A randomized double-blind study trial measuring TFC (up to 40 g daily) was terminated early due to futility criteria being reached. The use of creatine fails to delay functional decline in an early manifestation of HD [57]. In another controlled study, creatine (5 g/day; 1 year) treatment resulted in better muscle function capacity in patients with neuromuscular disease but did not show improvements in neuromuscular function and the cognitive status of stage I–III HD patients [88].
3.4.2. Coenzyme Q10
Coenzyme Q10 cofactor is involved in ATP production in the electron transport chain (ETC) of mitochondria, and its supplementation in HD patients may improve mitochondrial function [89]. It was neuroprotective in R6/2 mice, delaying motor deficit, atrophy, and inclusion, and extending survival [90,91]. In a phase III randomized clinical trial, coenzyme Q10 was not effective and the trial was stopped as the futility criteria were reached (
3.4.3. Eicosapentaenoic Acid (EPA)
Ethyl-EPA is a derivative of the n-3 polyunsaturated fatty acid EPA, which binds to the peroxisome proliferator-activated receptor of mitochondria [92]. Ethyl-EPA improves the neuronal function by inhibiting caspase and reducing mitochondrial damage by reducing the activity of the c-Jun N-terminal kinase (JNK) pathway [93,94]. Treatment with ethyl-EPA (2 g/day) showed a stable/improved motor function. However, intent-to-treat analysis showed no significant change between ethyl-EPA and placebo for total motor score 4 (TMS–4) subscale in HD patients (stage III) [95]. Patients with fewer CAG repeats showed significant improvement in TMS-4.
In a phase III, double-blind randomized control trial, ethyl-EPA did not show improvement in TMS, cognition or global impression over 6 months. After 6 months, all participants (both those in the treatment and placebo group) were given ethyl-EPA. Those in the original treatment group showed a better motor function (indicated by TMS scores). This suggests that ethyl-EPA needs a longer period before improvement can be observed which might possibly reflect a disease modification [96]. In a recent study, no significant improvement of the treatment group over placebo group was found in measures of TMS or UHDRS scores [59].
3.4.4. Cystamine and MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) Blockers
Both cystamine and MPTP increase the survival effects of HD cells and inhibit oxidative damage [60].
3.4.5. Meclizine
Meclizine, an antihistamine drug, inhibits oxidative metabolism and apoptosis, and is neuroprotective in drosophila model. Energy metabolism deficits and neuronal degeneration are hallmarks of HD, so treatment with meclizine is a potential strategy, especially since it crosses the BBB [20,61] (Table 1 and Figure 2). There is no human clinical trial for this drug listed in
3.5. Targeting Transcriptional Dysregulation
3.5.1. Sodium Phenylbutyrate
Administration of sodium phenylbutyrate (an HDAC inhibitor) to N171-82Q symptomatic mice showed less brain atrophy and extended survival rates. Further, it increased and decreased histone acetylation and methylation, respectively, in the rodent brain. It also downregulated caspases involved in apoptosis [62]. A dose-response study highlighted that sodium phenylbutyrate was safe, secure, effective and well-tolerable in HD patients [97].
3.5.2. HDACi4b
HDACi4b (a pimelic diphenylamide HDAC inhibitor) improves motor impairment as well as decreases neurodegeneration in mouse models of HD. Oral administration of HDACi4b to mice showed improvement in these motor deficits. These mice also showed less striatal atrophy and brain-size reduction. HDACi4b reversed hypoacetylation of the H3 histone subunit that occurs in the presence of mHTT, and mRNA expression was returned to normal levels [63].
3.5.3. Suberoylanilide Hydroxamic Acid (SAHA)
Histone acetylation in the brain is increased by SAHA (by inhibiting HDAC) which improves motor impairments in transgenic R6/2 mice. SAHA can be taken orally because it crosses the BBB, however, this has not been tested in humans [64].
3.5.4. Mithramycin and Chromomycin
Treatments with mithramycin and chromomycin (anthracyclin derivatives) promote epigenetic histone modifications in cultured R6/2 and N171-82Q transgenic cell lines, providing a basis for clinical trials for HD [65,98,99].
3.6. Agents Targeting Mutant Huntingtin
3.6.1. RNA Interference (RNAi) and Antisense Oligonucleotide (ASO)
ASO and RNAi execute their knockdown function by allele and nonallele-selective manners [100,101,102]. As an example, modified ASO (peptide nucleic acid i.e., PNA) enables the selective recognition of the mutant allele and selective inhibition of mHTT expression in human fibroblasts [103]. RNAi reduced neuropathology, improved motor behavior and extended viability in HD [102,104,105].
3.6.2. Intrabodies and Artificial Peptides
In transgenic mouse models of HD like R6/2, N171-82Q, YAC128, and BACHD, treatment with intrabody gene therapy improved body weight, motor function, cognitive, and neuropathological manifestation [66,106].
3.7. Nucleic Acid-Targeting Therapies
3.7.1. Therapies Targeting DNA
Currently, zinc finger proteins (ZFPs) and CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats-CRISPR-associated system) are under investigation.
ZFPs
ZFPs are one of the most abundant protein groups and have various functions, including regulation of DNA, RNA, and protein function. They can bind to specific sequences of DNA and can be used as therapeutic compounds. ZFPs reduce mHTT expression without affecting the expression of other genes/wild-type HTT [67,102,107].
CRISPR-Cas9
CRISPR-Cas9 is involved in viral defense mechanisms of bacteria which recognize and destroy foreign DNA. CRISPR-Cas9 is involved in the excision of CAG repeats to make harmless alleles and silence the mHTT expression by insertion of stop codon/missense mutations [68,108,109,110]. In HD140Q-knockin mice, it was demonstrated that CRISPR-Cas9 can be used to reduce mHTT and improve motor function, but not to increase the lifespan of these mice [69]. Ekman et al. showed that CRISPR-Cas9 can be used for mHTT editing, which can extend survival and improve motor function in the R6 mice following intrastriatal delivery [111].
3.7.2. RNA Targeting Therapies
The four major methods to inhibit the function of mHTT mRNA are: ASOs, RNAi compounds, novel viral vectors, and small-molecule splicing modulators.
ASO Approaches
ASO are single-stranded DNA (ssDNA) molecules that primarily bind to a specific sequence on RNA and regulate post-transcriptional gene expression [112]. The ssDNA diffuses well in the CNS and is taken up by neurons. Therefore, the injection of ASOs into the cerebrospinal fluid (CSF) results in ubiquitous delivery of drugs and suppresses the production of mHTT [70] (Table 1). However, ASO delivery has some side effects, like thrombocytopenia which was observed in some human trials of ASOs [113]. ASO can ameliorate transcriptional dysregulation and reduce the level of mHTT and improve behavior in the YAC128, YAC18, and BACHD mouse models of HD [114,115].
IONIS-HTTRx is an important ASO. It has 12–25 nucleotides and transforms phosphodiester linkages to phosphorothioate. IONIS-HTTRx caused a remarkable reduction in HTT mRNA and protein expression [71]. The injection of ASOs (conjugated with peptides), produced wide CNS distribution and longer life span in the spinal muscular atrophy (SMA) mouse model [116]. In a recent study of phase I–IIa trial, HTTRx lessened the concentration of mutant HTT in CSF of HD patients. Therefore, ASO compounds not only suppress the expression of HTT mRNA and the huntingtin protein in CNS, but also in CSF [117].
RNAi Approaches
RNA interference is a gene-silencing process that uses short interfering RNA (siRNA), short hairpin RNA (shRNA), bi-functional shRNA and microRNA (miRNA). The combination of neural progenitor stem cell therapy and RNAi therapy can ameliorate symptoms in mouse models of HD [118]. In the animal models (R6/1, R62, N171-82Q, RAT AAV-HD70d) of HD, siRNA, shRNA, and miRNA treatments have been used to reduce neuropathology and improve motor function [6,72,104]. AMT-130 (adeno-associated virus vector) contains an artificial miRNA which produces a huntingtin-lowering molecule. Side effects include peripheral neuropathy observed in clinical trials of siRNA. RNAi has been tested in rodents and its delivery system has been tested in nonhuman primates [119].
Small Molecule Approach
Small molecules like RG7800 showed ocular complications in the Δ7 mouse model of spinal muscular atrophy (SMA) [120], while the phase I trial of the molecule RG7916 (risdiplam) was recently completed (NCT02633709). RG7800 and RG7916 are splicing modifiers, which change the way the pre-mRNA is spliced so that it contains all the information necessary to make a functional protein. They promote the production of a full-length and functional protein from the gene. RG7800 increases the survival motor neuron (SMN) protein level by modifying the splicing of the SMN2 mRNA. RG7800 is shown to promote the inclusion of exon 7 in SMN2 mRNA, generating full-length mRNA, using fibroblasts from an SMA type I patient. In the SMA mouse model, the treatment of RG7800 showed a dose-dependent increase in SMN protein levels [121]. Oral administration of RG7800 in SMA patients increased the functional SMN protein level up to two-fold from baseline [122]. New work is now underway to identify these molecules and their possible role in the lowering of mutant HTT gene and protein expression [102,123].
3.8. Other Therapeutics Advancements
3.8.1. Ubiquilin
Ubiquilin overexpression in R6/2 mice decreased aggregation in the hippocampus and cortex and increased lifespan. However, its overexpression did not improve motor symptoms, and did not change the amount of aggregates in the striatum [75,76].
3.8.2. Chaperonins
TRiC (CCT1-CCT8 subunit) is an example of chaperonin which is involved in the folding of about 9–15% of the normal proteins [77] and inhibits aggregation of mHTT [78]. It reduced the number of inclusions, fibrillar oligomers, and insoluble mHTT fragments.
3.8.3. AFQ056
AFQ056 did not improve chorea in a randomized double-blind clinical trial [79].
3.8.4. BN82451
BN82451 inhibits cyclooxygenases and provides antioxidant, anti-inflammatory and neuroprotective effects [80]. It also improved motor function and survival, decreased brain atrophy, neuronal atrophy, and neuronal mHTT inclusions in the R6/2 mice [81]. Recently, a phase II clinical trial has been completed in male HD patients. As per
3.8.5. Antipsychotic Drugs
Antipsychotic drugs are used to treat chorea associated symptoms because they block or modulate dopamine receptors. Many antipsychotic drugs (especially typical antipsychotics) produce motor dysfunction resembling Parkinson’s disease (PD). Currently, a phase III trial comparing TBZ with olanzapine and tiapridal is under evaluation [39].
3.8.6. Antiapoptotic Drugs
Caspase cleavage (mainly caspase-3 and -6) occur in mHTT [83]. Mutating the caspase cleavage sites on mHTT leads to neuroprotection and prevents neurodegeneration in yeast artificial chromosome (YAC) mice that express mHTT. Caspase-3 and -6 resistant mice did not develop HD neurodegeneration, indicating that cleavage at these caspase sites plays an important role in neurodegeneration of HD [82,123,124].
3.8.7. Diet
Various studies indicate that a Mediterranean-type diet may delay the onset of other neurodegenerative diseases, like AD, PD, dementia and cognitive impairment [125]. Recently a study highlighted that a Mediterranean-type diet affects the time to HD phenoconversion. In fact, eating high amounts of dairy products was associated with an increased risk of phenoconversion. This may be due to a lower level of urate, which leads to a faster progression and manifestation of HD. These types of diet-related studies need further investigation [84,107,126]. Intermittent fasting promotes autophagy and cleared the mHTT [127].
3.9. Some Promising Clinical Trials
3.9.1. Cysteamine (CYST)
Cysteamine controls oxidation levels through increasing concentration of glutathione, activation of protein catabolism through the hindrance of transglutaminase and induction of heat shock proteins (HSPs) effects [128]. Inhibition of transglutaminase is the putative mode of action and is observed in R6/2 and zQ175 mouse models of HD [129]. The Cysteamine-HD phase II/III trials indicated a delay in the release of cysteamine in HD patients.
3.9.2. Pridopidine
Pridopidine is a modulator of the dopamine 2 receptor [130] and activates the sigma-1 receptor [131]. In the most recent trials of pridopidine, no improvement in motor symptoms (unified Huntington’s Disease rating scale - total motor score (UHDRS-TMS)) was observed with placebo [132,133,134]. High level of pridopidine is found in brain-derived neurotrophic factor (BDNF) and diminishes mHTT aggregate size and improved motor performance in R6/2 mice [135,136]. In an early-stage HD, improvement in the total motor score (TMS) was observed in treated patients [136,137].
3.9.3. Triheptanoin
Triheptanoin is a triglyceride that reverses the metabolic defects in HD by supplying substrates to the Krebs cycle [138]. Recently, a phase II study using triheptanoin was conducted in the early phase of HD patients (listed at
3.9.4. Latrepirdine (Dimebon)
Latrepirdine stabilize and enhance mitochondrial membranes and functions. In a short duration trial, latrepirdine promoted cognitive improvement (MMSE) in mild to moderate HD patients [11,139]. At the time of writing this, a total of 13 clinical trials using latrepirdine have been reported on
3.9.5. Amantadine
Amantadine is a weak NMDA receptor blocker [140] and increases dopamine release [141]. Amantadine reduces dyskinesias in HD, without provoking parkinsonism [142].
3.9.6. Lamotrigine
Lamotrigine is an antiepileptic drug and decreases glutamate release by blocking voltage-gated sodium channels [143,144]. It reduces motor symptoms and elevates mood in HD patients [145].
3.9.7. Selisistat
Selisistat is a selective SirT1 inhibitor which removes acetyl groups on proteins, including mHTT. Therefore, blocking the deacetylation of mHTT should activate clearance. In early-stage HD patients, selisistat improved TMS, but not in most measures of cognition, mood, and functionality [146,147].
3.9.8. Tauroursodeoxycholic Acid/Ursodiol
Tauroursodeoxycholic acid (TUDCA) is a bile acid and has antiapoptotic properties in a mouse model of HD. Mice given TUDCA showed less striatal atrophy, apoptosis, and reduced locomotor and sensory-motor defects [148]. A commercially available uroursodeoxycholic acid precursor, ursodiol, has been examined in a phase I trial, but to date, not reported.
3.9.9. Laquinimod
Laquinimod reduces the expression of Bax, responsible for the release of cytochrome C from mitochondria and activation of caspases, causing apoptosis and production of toxic mHTT fragments. This drug improves motor function and reduces depressive behaviors in mice. It is recently undergoing a phase II clinical trial in human HD patients [149]. Laquinimod ameliorates myelination deficiency and behavioral deficits in the YAC128 mouse model of HD [150,151].
3.9.10. Kynurenine Inhibitors
The enzyme indoleamine 2,3 dioxygenase (IDO1) catalyzes the conversion of tryptophan into kynurenine. Kynurenine is then metabolized into 3-hydroxykynurenine (3-HK) and quinolinic acid, both of which are neurotoxic and are increased in HD. In contrast, kynurenine is also metabolized into kynurenic acid, which is neuroprotective. In HD, an imbalance exists between the neurotoxic products and neuroprotective products and targeting the rate-limiting step of IDO1 could effectively shift the balance toward neuroprotective [152]. Kynurenine 3-monooxygenase is the enzyme that catalyzes the conversion of kynurenine into 3-HK. Treating microglial cells from R6/2 mice with a kynurenine 3-monooxygenase inhibitor (Ro 61–8048) showed dramatically reduced 3-HK levels compared to the vector containing cells [153].
4. Conclusions and Future perspectives
The current therapeutic investigations of HD mainly focus on excitotoxicity, dopamine pathway, caspase inhibitors, mHTT aggregation, mitochondrial dysfunction, transcriptional dysregulation, and diet. The application of robust molecular imaging and digital biomarkers may provide a valuable therapeutic boost to the design of clinical trials. Additionally, the increased openness of regulatory agencies for effectiveness will also promote the development of clinical trials. The advancement of modern technologies, and the availability of various promising agents/molecules enable the development of therapies which will further improve the quality of research and outcomes in HD patients. The most promising drugs are those that target the production of mHTT protein and block its actions.
Author Contributions
Conceptualization, A.K., V.K. J.-J.K.; methodology, A.K., V.K.; writing—original draft preparation, A.K., V.K.; writing—review and editing J.-J.K., S.K., V.K., Y.-M.L., Y.-S.K., A.K., K.S. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Conflicts of Interest
The authors declare no conflicts of interest.
Abbreviations
| Abnormal involuntary movements scale | AIMS |
| Alzheimer’s disease | AD |
| Antisense Oligonucleotide | ASO |
| Blood-brain barrier | BBB |
| Brain-derived neurotrophic factor | BDNF |
| Clustered regularly interspaced short palindromic repeats-CRISPR-associated system | CRISPR-Cas9 |
| Cerebrospinal fluid | CSF |
| Cytosine-adenine-guanine | CAG |
| Eicosapentaenoic acid | EPA |
| Electron transport chain | ETC |
| Food and Drug Administration | FDA |
| Huntington disease | HD |
| Huntingtin gene | HTT |
| micro RNA | miRNA |
| Mini-mental state examination | MMSE |
| Mutant huntingtin protein | mHTT |
| Mammalian target of rapamycin | mTOR |
| 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine | MPTP |
| N-methyl-D-aspartate | NMDA |
| Parkinson’s disease | PD |
| RNA Interference | RNAi |
| small interfering RNA | siRNA |
| Spinal muscular atrophy | SMA |
| Suberoylanilide hydroxamic acid | SAHA |
| Tauroursodeoxycholic acid | TUDCA |
| Tetrabenazine | TBZ |
| Total functional capacity | TFC |
| Total motor score | TMS |
| Unified HD rating scale | UHDRS |
| Vesicular monoamine transporter 2 | VMAT2 |
| Zinc finger proteins | ZFPs |
Figures and Table
Enlarge this image.Figure 1. Mechanism of Toxicity of Huntingtin (HTT) gene. NO (Nitric Oxide), CAG (cytosine-adenine-guanine).
Enlarge this image.Figure 2. Recent advancement in the therapeutics for Huntington’s disease. TBZ (Tetrabenazine); EPA (eicosapentaenoic acid); MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); SAHA (suberoylanilide hydroxamic acid); HDACi4b (histone deacetylase inhibitors); RNAi (RNA interference); ASO (antisense oligonucleotide); ZFP (zinc finger protein); CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats); miRNA (micro RNA); siRNA (small interfering RNA).
Recent status of Huntington’s disease (HD) drug therapy.
| Drug/Reagent | Primary Target (Mechanism of Action) | Status and Principal Result | Ref. |
|---|---|---|---|
| (1) Drugs against excitotoxicity | |||
| Riluzole | Glutamate release inhibitor | Does not show efficacy in human trails | [31] |
| Memantine | N-methyl-D-aspartate (NMDA) receptor inhibitor | Demonstrated efficacy in human trial | [32,33] |
| Tetrabenazine (TBZ) | Dopamine pathway |
Approved by food and drug administration (FDA) for treatment of chorea in HD | [38,39,40] |
| (2) Targeting Caspase and huntingtin (HTT) proteolysis | |||
| Minocycline | Caspase-dependent and independent neurodegenerative pathway | Inhibits caspase-1 and -3 mRNA upregulation, and decreases inducible nitric oxide synthetase |
[42,44,45] |
| (3) Targeting HTT aggregation and clearance | |||
| Congo red and Trehalose | Aggregation | Showed efficacy in a rodent model | [46,49] |
| Compound C2–8 | Aggregation | Showed efficacy in a rodent model | [53] |
| Rapamycin | Aggregation |
Showed efficacy in a rodent model | [54,55] |
| (4) Targeting mitochondrial dysfunction | |||
| Creatine | Mitochondrial dysfunction | Attained futility in human trial | [57] |
| CoQ10 | Mitochondrial dysfunction | Attained futility in human trial | [58] |
| Eicosapentaenoic acid (EPA) | Mitochondria dysfunction | A mixed scenario of positive and negative trial | [59] |
| Cystamine and mitochondrial permeability transition pore blockers | Mitochondrial dysfunction | Showed efficacy in a rodent model | [60] |
| Meclizine drug | Mitochondrial dysfunction | Showed efficacy in the fly model | [61] |
| (5) Targeting transcriptional dysregulation | |||
| Sodium phenylbutyrate | Transcriptional deregulation |
Showed efficacy in a rodent model | [62] |
| HDACi4b (a pimelic diphenylamide HDAC inhibitor) | Transcriptional deregulation |
Showed efficacy in a rodent model | [63] |
| Suberoylanilide hydroxamic acid | Transcriptional deregulation |
Showed efficacy in a rodent model | [64] |
| Mithramycin and chromomycin | Transcriptional deregulation |
Showed efficacy in a rodent model | [65] |
| (6) Targetting mutant huntingtin (mHTT) | |||
| RNA interference and antisense oligonucleotide (ASO) | Blocks transcription of mHTT | Showed efficacy in a rodent model | [6] |
| Artificial peptides and intrabodies | Targeting proline-rich domain of HTT | Showed efficacy in a rodent model | [66] |
| (7) Therapies targeting nucleic acid | |||
| Zinc finger protein | Reduced mutant protein expression | Showed efficacy in a rodent model | [67] |
| CRISPR-Cas9 | Excision of CAG repeat and, reduction of mutant HTT | Showed efficacy in a rodent model | [68,69] |
| ASO approach (IONIS-HTTRX, Peptide conjugated ASOs) | Reduction in HTT mRNA and protein | Showed efficacy in a rodent model | [70,71] |
| RNAi approach (siRNA, shRNA, and miRNA) | Improves motor and neuropathological abnormalities, silencing of HTT | Showed efficacy in a rodent model | [6,72] |
| Novel Viral Vectors (AAV1, AAV5, AAV9, AAV-PHP.B, CREATE) | Widespread transduction of cells | Showed efficacy in primate and rodent models | [73,74] |
| (8) Other therapeutics | |||
| Ubiquilin | Reduces mHTT aggregation | Showed efficacy in a rodent model | [75,76] |
| miRNA | Silence HTT | Testing in rodent and nonhuman primates | [6,72] |
| Chaperonins | Decrease mHTT aggregation | Showed efficacy in a rodent model | [77,78] |
| AFQ056 | The antagonist for glutamate receptor 5 | Showed no improvement in chorea in a clinical trial | [79] |
| BN82451 | Decreases glutamate release by blocking Na+ channels | Showed efficacy in a rodent model | [80,81] |
| Antipsychotic drug | Block or modulate dopamine receptors | Under phase III trial | - |
| Antiapoptotic drug | Cleave mHTT | Effective in mice model | [82,83] |
| Diet | Delay onset of disease | Effective result but requires further evaluation | [84] |
© 2020 by the authors.
Details
; Singh, Kritanjali 3 ; Kumar, Sukesh 4 ; You-Sam, Kim 2 ; Yun-Mi, Lee 2 ; Jong-Joo, Kim 2 1 Department of Genetics, Sanjay Gandhi Post-Graduate Institute of Medical Sciences, Lucknow 226014, UP, India;
2 Department of Biotechnology, Yeungnam University, Gyeongsan, Gyeongbuk 38541, Korea;
3 Central Research Station, Subharti Medical College, Swami Vivekanand Subharti University, Meerut 250002, India;
4 PG Department of Botany, Nalanda College, Bihar Sharif, Magadh University, Bihar 824234, India;